The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 09, 2012
Filed:
Apr. 04, 2011
Stephanie Hachtel, Frankfurt, DE;
Juergen Dedio, Mainz-Kastel, DE;
Holger Heitsch, Mainz-Kastel, DE;
Werngard Czechtizky, Frankfurt, DE;
Sven Grueneberg, Kelkheim, DE;
Stephen J. Shimshock, Hillsborough, NJ (US);
Raymond W. Kosley, Jr., Bridgewater, NJ (US);
Carolina L. Lanter, Audubon, PA (US);
Hui LI, Neshanic Station, NJ (US);
Rosy Sher, Bridgewater, NJ (US);
Aleksandra Weichsel, Tucson, AZ (US);
Stephanie Hachtel, Frankfurt, DE;
Juergen Dedio, Mainz-Kastel, DE;
Holger Heitsch, Mainz-Kastel, DE;
Werngard Czechtizky, Frankfurt, DE;
Sven Grueneberg, Kelkheim, DE;
Stephen J. Shimshock, Hillsborough, NJ (US);
Raymond W. Kosley, Jr., Bridgewater, NJ (US);
Carolina L. Lanter, Audubon, PA (US);
Hui Li, Neshanic Station, NJ (US);
Rosy Sher, Bridgewater, NJ (US);
Aleksandra Weichsel, Tucson, AZ (US);
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, DE;
Abstract
The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.